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Abstract
Background: Many smoking-cessation programs and pharmaceutical aids demonstrate substantial health gains for
a relatively low allocation of resources. Genetic information represents a type of individualized or personal feedback
regarding the risk of developing lung cancer, and hence the potential benefits from stopping smoking, may
motivate the person to remain smoke-free. The purpose of this study was to explore what the impact of a genetic
test needs to have within a typical smoking-cessation program aimed at heavy smokers in order to be cost-
effective.
Methods: Two strategies were modelled for a hypothetical cohort of heavy smokers aged 50 years; individuals
either received or did not receive a genetic test within the course of a usual smoking-cessation intervention
comprising nicotine replacement therapy (NRT) and counselling. A Markov model was constructed using evidence
from published randomized controlled trials and meta-analyses for estimates on 12-month quit rates and long-
term relapse rates. Epidemiological data were used for estimates on lung cancer risk stratified by time since
quitting and smoking patterns. Extensive sensitivity analyses were used to explore parameter uncertainty.
Results: The discounted incremental cost per QALY was AU$34,687 (95% CI $12,483, $87,734) over 35 years. At a
willingness-to-pay of AU$20,000 per QALY gained, the genetic testing strategy needs to produce a 12-month quit
rate of at least 12.4% or a relapse rate 12% lower than NRT and counselling alone for it to be equally cost-effective.
The likelihood that adding a genetic test to the usual smoking-cessation intervention is cost-effective was 20.6%
however cost-effectiveness ratios were favourable in certain situations (e.g., applied to men only, a 60 year old
cohort).
Conclusions: The findings were sensitive to small changes in critical variables such as the 12-month quit rates and
relapse rates. As such, the cost-effectiveness of the genetic testing smoking cessation program is uncertain. Further
clinical research on smoking-cessation quit and relapse rates following genetic testing is needed to inform its cost-
effectiveness.
Background
Smoking remains a substantial health problem in many
countries and is the largest modifiable risk factor for
several cancers and a host of chronic diseases. Between
1980 and 2004, smoking prevalence in the Australian
population dropped from 40% to 21% [1] partly due to
progressive tobacco control policies such as cigarette
taxation, smoke-free workplaces and extensive public
education campaigns. However, smokers remain a
large proportion of the population (21%) as in other
European countries (around 30%) [2]. It has been pro-
posed that while system-level public health approaches
are effective at reducing aggregate smoking levels, a
‘one size fits all’ approach may not be effective for all
types of smokers [3].
The pivotal paper by Cromwell J et al. (1997) demon-
strated the cost-effectiveness of smoking-cessation pro-
grams delivered by a general practitioner (GP) [4]. Many
subsequent smoking-cessation programs have also
demonstrated substantial health gains for a relatively low
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effective, smoking-cessation programs still suffer from
low success rates in terms of numbers of quitters at
12-months. As a general guide, the 12-month quit rates
are around 6% for brief GP advice, 9% for proactive
counselling, 6-12% for nicotine replacement therapies
with counselling, and 12-19% for pharmacotherapies with
counselling [6]. The extent of relapse following successful
smoking-cessation further erodes their effectiveness. This
suggests that many smokers may require other measures,
such as targeted or personalised information, to encou-
rage cessation and abstinence.
While tobacco smoking is the largest known risk fac-
tor for lung cancer occurring in 85-90% of cases, only
10-15% of smokers develop lung cancer [7]. Recent evi-
dence suggests that this may be partly due to differences
in genetic susceptibility to lung cancer [7,8]. That is, the
smoking-gene interaction means that some smokers are
at greater risk of developing lung cancer, with several
host characteristics (i.e., K-ras, GSTM1, CYP2D6,
c-MET, NKX2-1, LKB1, BRAF) implicated in lung cancer
onset [9]. Further, other genes are implicated in other
chronic diseases linked withs m o k i n g ,t h e r e f o r es m o k -
ing-cessation has wider health benefits and therefore is
always beneficial.
The genetic link to lung cancer has implications for
the design of smoking-cessation programs. Genetic
information represents a type of individualized or perso-
nal feedback regarding the risk of developing lung can-
cer, and hence the potential benefits from stopping
smoking, may motivate the person to remain smoke-
free. Central to this is the potential to address the issue
of optimistic bias, the underestimation of one’s own risk
of a harmful outcome relative to the average smoker.
Recent developments in genetics suggests that some
people respond well to genetic information about risk of
lung cancer [10,11], are more likely to quit [12] and per-
haps less likely to relapse. Combining a genetic test with
a smoking-cessation program might enhance the effec-
tiveness and thus represent a cost-effective intervention.
Several companies now offer genetic testing for lung
cancer susceptibility however they offer a single nucleo-
tide polymorphism (SNP) test for lung cancer risk result
and no other clinical data is used for their risk assess-
ment. Our author (R.Young) heads a clinical research
program at Auckland Hospital, New Zealand, offering
patients a SNP-based test involving 20 SNPs and assess-
ment of other clinical variables (family history, COPD,
smoking patterns) within usual clinical practice for
smoking-cessation. Early results show that intentions to
quit smoking among 250 participants based on genetic
testing for lung cancer risk were around 88% in those at
elevated risk of lung cancer. The economic value of the
adopting this new technology into practice is yet to be
determined.
To date, no smoking-cessation study has examined the
cost-effectiveness of offering genetic tests in the context
of disease prevention but other studies have investigated
genetic testing to guide the choice of pharmacotherapy
among individuals attempting to stop smoking [13,14].
Genetic testing imposes costs on individuals, doctors
and the health system. Thus, if genetic testing is to be
offered in addition to a first-line smoking-cessation pro-
gram, then it must result in enough new quitters (or
reduced numbers of relapsers) in order to justify the
costs. The purpose of this study was to explore how
much of an impact genetic testing information would
need to have in order to be a cost-effective addition to a
typical smoking-cessation program. Specifically, we
assess the net costs, and health benefits of a smoking-
cessation program with a genetic test compared with
nicotine replacement smoking-cessation treatment.
Methods
Markov model structure
A Markov state transition model was constructed in
TreeAge Pro 2009 software (TreeAge Software Inc,
Williamstown, MA, USA) (Figure 1). The model, known
as a Markov single cohort model, is cyclical, with
patients moving between specified health states at the
end of each cycle, with subsequent cost and quality of
life implications. The advantage of this type of model is
that it explicitly identifies the sequence and linkage of
events under consideration and allows detailed analyses
on data parameters. Two decision strategies were mod-
elled; individuals either received or did not receive a
genetic test component within the course of a usual
smoking-cessation intervention. The model tracked a
hypothetical cohort of smokers over 35 years from age
50 who faced different probabilities of quitting smoking,
risk of developing lung cancer and transferring between
different health states (Table 1). Relapse rates in the
years beyond a successful quit attempt and continued
abstinence at 12 months were included [15]. The model
consists of five health states: no lung cancer (quit smok-
ing), no lung cancer (stay smoking), early lung cancer
(stage I or II), advanced lung cancer (stage III or IV),
and death. Individuals will either continue or quit smok-
ing at 12 months following either intervention and be
allocated to ‘no lung cancer’ in the first annual cycle.
Next they are dispersed into the various pathways or
health states according to certain probabilities (Table 1).
‘Tunnel’ features have been built into the model for
lung cancer states to ensure that the risk of cancer pro-
gression or death is dependent upon the duration since
diagnosis. Tunnel states are a ‘time in state’ feature that
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state rewards and transition probabilities can be altered
for each cycle patients spend in the tunnel state [16].
The model is calculated by summing the expected
(mean) values at each tree node for each course of
action and aggregates the longer-term health outcomes
and costs for the two intervention strategies.
Description of the two strategies
We compared a usual smoking-cessation program with
an alternative involving the usual smoking-cessation pro-
gram and a genetic test some point after (e.g., 6 weeks)
completing the program (as per McBride et al. 2002
[12]). The benefit of this test is to decrease the likelihood
that an individual will relapse and begin smoking again
as measured by relapse rates at 12 months.
In our model, we assumed our cohort were 50 year
old heavy-smoking men and women (>20 cigarettes per
day) who presented to their GP, and were willing to par-
ticipate in a smoking-cessation program. The usual
smoking-cessation program comprised of GP advice, tel-
ephone counselling and nicotine replacement therapy
(NRT) administered over 12 weeks (Table 2). Although
there are new pharmacological therapies available that
show superior smoking-cessation rates (i.e., bupropion,
varenicline 12-19% [6]) than those for NRT (6% [17]),
NRT is widely available, accepted in most countries and
has only minor adverse side-effects or contraindications.
Furthermore, it is cost-effective and recommended first-
line therapy in clinical practice guidelines for smoking
cessation in Australia [6]. The genetic testing option is
assumed to include a blood sample and assessment of
other lung cancer risk factors. A second doctors’ visit is
required so that the doctor can communicate the test
results and overall risk assessment to the individual who
is also presented with a booklet explaining the test
results.
Data parameters in the model
The data used to populate the model was based on pub-
lished literature, national reports and government cancer
statistics, however a number of assumptions were also
necessary (Additional file 1, Table S1). The key para-
meters in the model were quit rates in the two arms
and, for the genetic test arm, we have assumed that
these behaviour changes have occurred regardless of the
Figure 1 Illustration of Markov Model.
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reviews and results of meta-analyses were used to
inform estimates on 12-month quit rates of NRT [17]
and relapse rates beyond 12 months [15]. Although it is
possible to that ‘natural’ quitters, those needing no assis-
tance to quit smoking, may exist in both groups, we
have assumed the natural quit rate is equivalent in both
arms. Risk estimates of lung cancer are dependent on
gender, time since quitting and smoking frequency and
were derived from a cohort study of over 463,000 US
men and women [18]. Current epidemiological evidence
provided information on background incidence of lung
cancer by stage, mortality and survival rates of lung can-
cer, and all-cause mortality among smokers. To reflect
changing estimates as the cohort ages, we accounted for
age-dependent variables using tabulated data in our
model. Table 1 lists all data estimates and tabled data in
the model with their respective sources and ranges
tested in the sensitivity analyses.
Outcome measures
The measures of benefit in the evaluation were the
number of quitters and quality-adjusted life-years gained
(QALYs) over 35 years. The number of quitters at
12 months is also presented to highlight the shorter-
term impact. The level of effectiveness of smoking-
cessation enhanced with a genetic test was based on a
randomised clinical trial involving 557 participants [12].
The proportion of individuals achieving continued absti-
nence at 12 months was 11% compared with 5% in the
NRT only arm (p = 0.08). This study was chosen as it
included the comparison groups most relevant for an
Australian setting, that is, NRT plus counselling with or
without a genetic test. McBride’ss t u d yw a sa l s o
Table 1 Data parameters used in model: description, base case estimate, range tested in one-way sensitivity analyses
and sources
Parameter description Base estimate Range
tested
Sources
Quit rates: 12-month continuous abstinence
a) Genetic Test 11% 7-22% [12]
b) Usual treatment 6% 3-12% [17]
Relapse rate after 12-month quit 10% in years 2-6, 4% after
1 [15]
Lung cancer incidence Annual from age 40, e.g., 0.0018024 at age 65 years
1 [32]
Relative risk of lung cancer in heavy smokers compared
to general population
6.609 and [18]
Relative risk of lung cancer in ex-smokers compared to
general population
Annual from 5-year age group by time since quit e.g, ages
50-55 years RR = 4.75
1
Survival/mortality rates (background population) Annual by age e.g, age 65 annual dying rate = 0.00936
1 ABS Life Tables
2005-07
2
Survival rates of lung cancer Annual survival at 1 year 36% to 12% at 5 years AIHW [33]
Proportion of
a) early lung cancer 20% 13-23% [33], authors
assumption
3
b) adv lung cancer 80% 77-87%
Utility scores
a) Early stage lung cancer (I&II) 0.73 0.69-0.83 [23,34]
b) Adv stage lung cancer (III&IV) 0.66 0.30-0.76 [23,34]
c) No lung cancer 1 - authors
assumption
Lung cancer healthcare costs
a) Early lung cancer 1st year (NSCLC only) 44,274 [35,36]
b) Adv lung cancer + SCLC 1
st year 27,057 All ± 30% [35,36]
c) Ongoing costs (stable disease) 7,115 [36,37]
d) Progressive disease 10,945 [36,37]
e) Terminal care (final year) 9,961 [36,37]
1. Tables are used rather than one point estimate to account for different values that change over time. Values will alter when individuals age.
2. Epidemiological data and cost data are from slightly different years; data from these life-tables are from 2005-2007 while costs in 2009 AU$.
3. A proportion of approx. 8% of lung cancers are ‘unstaged’ but to avoid losing these people in the model, the proportion unstaged was assumed to be equally
split into early and advanced disease groups.
Abbreviations: ABS - Australian Bureau of Statistics, AIHW - Australian Institute of Health and Welfare, NSCLC - non-small cell lung cancer, SCLC - small cell lung
cancer.
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lytical approach and included largely lower socio-eco-
nomic smokers. Three other studies assessing the
impact of genetic susceptibility on smoking-cessation
[19-21] did not investigate relevant comparators includ-
ing one with no control group, were non-randomized or
had earlier-time quit rates. These quit rates ranged from
6-19%. Evidence for the effectiveness of NRT alone was
b a s e do nap u b l i s h e ds y s t e matic review of 136 rando-
mized controlled trials, over 40,000 participants and
yielding a summary estimate of 6% [17]. In the absence
of outcomes of genetic testing on smoking-cessation
beyond 12-months, we assumed relapse rates from the
literature were equivalent in the two arms.
The QALY is a generic outcome measure preferred
for use in economic evaluations combining survival time
adjusted for quality of life. A structured literature review
was undertaken to locate recent preference-based quality
of life scores (or utility weights) for lung cancer. Eleven
studies from 1997-2008 were uncovered. The utility
w e i g h t su s e di nt h ep r e s e n ts t u d yw e r eb a s e do nd i r e c t
utility assessment using standard gamble interviews [22]
and a second study that used the EuroQol 5D question-
naire [23]. These studies were chosen because utilities
were available for advanced/early stage and stable/pro-
gressive lung cancer, were more likely to reflect current
treatment patterns and side-effects [22] and reported a
range of scores to acknowledge uncertainty [22,24].
Analysis
The costs and outcomes for the two options were com-
bined into incremental cost-effectiveness ratios (ICERs),
that is, incremental cost per quitter and incremental
cost per QALY gained. The ratios are calculated as fol-
lows:
ICER
CC
EE
GT USC
GT USC
=
−
−
Where C = costs, E = effects (QALYs or quitters), GT =
genetic testing arm and USC = usual smoking-cessation
arm and represent the additional costs per health benefit
of the genetic testing component. Our analysis took a
payer perspective when measuring and valuing resources
used for the two options. This included two payers; the
consumers and health providers and the analysis aggre-
gated the costs from both payers. Direct costs borne by
the consumers (smokers) included over-the-counter
NRT and the genetic test (Table 2). Health providers
primarily bear the cost of lung cancer diagnosis, treat-
ment and follow-up care and health care counselling and
advice during smoking-cessation programs. Costs and
effects were discounted at 5% and brought forward to
2009 Australian dollars using the health component of
the Consumer Price Index.
Sensitivity and scenario analyses
Threshold analyses were undertaken to separately deter-
mine at what quit and relapse rates the genetic testing
arm was cost-effective. To determine if any variables
were primarily driving the cost-effectiveness results,
one-way sensitivity analyses on all parameters were
undertaken (Table 1). Of particular importance is the
12 month quit rate of 11% following a genetic test
Table 2 Intervention components and unit costs for usual smoking-cessation (USC) and USC plus genetic test
Qty Unit cost 2009 AU$ Source
USC (NRT with telephone counselling)
1 GP visit Standard 5-25 minutes 1 21.00 21.00 [6] MBS item 53
2 Patches 1st step - 21 mg/6 pkts 6 47.95 287.70 Retail pharmacy
1
(10 weeks) 2nd step - 14 mg/2 pkts 2 27.95 55.90
3rd step - 7 mg/2 pkts 2 27.95 55.90
3 Phone counselling Initial + 4 sessions 5 75.74 378.70 DVA, $119.75 initial then $83.70/hr
4 Booklet Self-help materials 1 2.90 2.90 [6]
Total 802.10
USC + Genetic test
1 USC as above 802.10
2 Clinic visit Standard 5-25 minutes 2 21.00 42.00 MBS online schedule, item 53
3 Test Blood sample, transfer to lab and analysis 1 311.00 311.00 [13]
4 Test booklet Explains results of gene test 1 2.90 2.90 Assumption - same for quit booklet
Total 1158.00
1. Price is based on the sale price at a large, urban pharmacy in Brisbane, AUD in 2008. Prices will vary according to conditions and place of purchase (e.g.,
online pharmacy suppliers vs. neighbourhood pharmacies). Note that the choice of the appropriate price does not impact on the results from the cost
effectiveness analysis as the cost is common to both arms of the model.
2. Abbreviations: USC - usual smoking cessation, NRT - nicotine replacement therapy, MBS - Medicare Benefits Schedule, DVA - Department of Veteran’s Affairs,
pkts - packets.
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of the results to the quit rates was explored by examin-
ing quit rates of 7%, 15% and 22% for the genetic test
option, and 3%, 9% and 11% for the usual smoking-
cessation program. Relapse rates were also halved to
explore the optimistic scenario commonly used in pre-
vious work [4,25,26]. Break-even analysis was used to
identify the quit rate required for the genetic test to be
cost-effective compared with usual smoking-cessation.
A probabilistic sensitivity analysis was also performed,
re-sampling from nominated distributions of data inputs
through 10,000 iterations. Beta distributions were
assigned to probabilities (e.g., quit and relapse rates,
health state transitions) and gamma distributions were
assigned to cost variables because these are often right-
skewed. The simulated mean ICER (QALYs) with 95%
confidence intervals (CI) was generated. Finally, to
assess the structural uncertainty of our model, we re-
examined the model for men and women separately
because it is well known that men are heavier smokers
and have higher risks of lung cancer compared to
women. We also explored the model for all persons
starting at age 30 and 60 years. During our analyses, we
assumed a willingness-to-pay ICER threshold of $20,000
per QALY gained to guide the interpretation of the find-
ings, a level in keeping with higher-end cost-effective-
ness ratios found in previous evaluations of smoking-
cessation programs [5].
Results
The cost-effectiveness results suggest that for smokers
offered a smoking cessation program with a genetic test,
an additional $300 on average is incurred compared
with a usual smoking-cessation program (Table 3). For
the smoking-cessation program with the genetic test,
the corresponding mean discounted QALYs were 14.288
compared with 14.298 QALYs for usual smoking cessa-
tion. Compared with usual smoking-cessation, the
genetic testing strategy produced an incremental cost-
effectiveness ratio of AU$27,572 per QALY gained
(Table 3) over 35 years.
These results suggest an ICER above the threshold
level of AU$20,000 per QALY gained. We found that
the 12-month quit rate would need to be at least 12.4%,
or that the long-term relapse rate needed to be 12%
lower, for the genetic testing strategy to be as cost-
effective as the usual smoking-cessation strategy (Addi-
tional file 1, Figures S1 & S2). The predicted propor-
tions of the cohort who quit or relapsed for both
strategies by age are highlighted in Additional file 1,
Figure S3 and similarly for those with early and
advanced lung cancer in Additional file 1, Figure S4.
Over a short-term 12-month period, for every 1000
individuals undertaking smoking-cessation enhanced
with a genetic test, an additional cost of $355,600 would
result in 50 additional quitters or $7,112 per additional
quitter over 12 months compared with usual smoking-
cessation (Table 3).
Sensitivity & scenario analyses
One-way sensitivity analyses indicated that the model
was highly volatile to changes in quit rates in both inter-
vention arms and the relative risks of lung cancer for
smokers and ex-smokers (Additional file 1, Figure 5).
Under more favourable scenarios, when the quit rate of
22% for genetic testing was used, the ICER was $2,203
Table 3 Results of incremental cost-effectiveness ratios (ICER) in base case and probability sensitivity analysis
Short-term (at end of 12-months) NRT + counselling NRT + counselling
+ genetic test
Difference
Cost for 1000 persons in each arm $802,100 $1,158,000 $355,600
Number of quitters @ 12 months 60 110 50
ICER - per quitter @ 12 months - - $7,112
Long-term (at end of 35 years)
Mean cost per person $6,600 $6,900 $300
QALYs gained per person 14.288 14.298 0.0109
ICER - QALYs gained per person - - $27,572
1
Monte Carlo simulated ICERs Incremental costs
2 Incremental
QALYs
ICERs (QALYs) (95% CIs)
Base case ICER $299.46 0.0109 $34,687
3 ($12,483, $87,734)
Initial cohort aged 30 years $341.69 0.0032 $133,409 ($53,502, $361,376)
Initial cohort aged 60 years $275.66 0.0126 $27,601 ($8,783, $73,948)
Men only (aged 50 years) $286.23 0.0130 $27,182 ($9,200, $70,783)
Women only (aged 50 years) $334.53 0.0049 $46,408 ($17,199, $118,383)
1. ICER of simple average results - single mean cost and effect differences.
2. Statistically significantly different mean costs and effects between groups (p < 0.001).
3. Average ICER of 1,000 simulations, not ICER of average results.
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as may be the case if the technology became less expen-
sive over time, the ICER was $8,247 per QALY. In a
two-way analysis, when the quit rates were 22% and
12% for the genetic testing and usual care arms respec-
tively, the ICER was $5,553 per QALY. Probabilistic sen-
sitivity analyses indicated a mean ICER of $34,687 per
QALY gained (95% CI $12,483, $87,734) (Table 3). Our
simulated base ICER of $34,687 per QALY gained was
somewhat higher than our simple ‘expected value’ base
ICER of $27,572 because the simulated ICER is calcu-
lated from the average of 10,000 mean costs and mean
effects based on several uncertain parameters with their
assigned distributions while the simple ICER is based on
fixed mean cost and effect estimates. The simulated
ICER sampling mean estimates are the correct and pre-
ferred ‘expected values’ for the model. At a willingness
to pay of $20,000 per QALY gained and using conserva-
tive estimates, the probability that the genetic test
option is a cost-effective addition to the usual interven-
tion is 20.6% (Figure 2) compared with 99.9% using
more optimistic quit rates for the two arms.
The cost-effectiveness ratios were lower than our base
case when applied to men only $27,182 per QALY (95%
CI $9,200, $70,783) and higher for women $46,408 per
QALY (95%CI $17,199, $118,383) (Table 3). When we
assessed the model with younger initial cohort of 30
year olds, the cost per QALY ratios increased to
$133,409 (95%CI $53,502 $361,376) and for 60 year
olds, decreased to $27,601 (95%CI $8,783, $73,948)
(Table 3). If it was assumed that the relapse rate is
halved in both strategies (i.e., 5% relapse from years 2-6,
2% thereafter), the mean ICER per QALY gained was
$18,623 (95%CI $5,897, $49,228). The relapse rate
would need to be zero in both arms, and the quit rate
for genetic-testing option at least 18%, for the genetic-
testing option to have lower costs and higher effects
than usual smoking-cessation. Alternatively, keeping the
relapse rate at our base level (10% years 2-6, 4% there-
after), the quit rate for the genetic-testing option needs
to be at least 29% to dominate the usual smoking-
cessation option.
Discussion
The purpose of this paper was to examine the potential
cost-effectiveness of smoking-cessation via NRT enhanced
with genetic information on lung cancer risk using a
dynamic model and up-to-date data estimates. Our results
suggest that using the 12 month quit rate reported in a
previous trial [12], the genetic testing option is unlikely to
be cost-effective at a threshold of $20,000 per QALY
gained. The genetic test option would need to achieve a
12-month continuous quit rate of 12.4% or more for it to
be a cost-effective addition to NRT and counselling treat-
ment alone. Alternatively, the genetic testing option would
need to achieve relapse rates 12% lower than those for
usual smoking-cessation. Although our base ICER $34,687
per QALY is higher than the $20,000 threshold, we
emphasize that the high volatility in the model estimates
means that the genetic test option could easily become
cost-effective if further evidence supported mildly more
optimistic quit or relapse rates. However, overall we found
very small differences in cost between the two options
over a period of 35 years and similarly for differences in
effects. The model was very sensitive to small changes in
critical variables such as the 12-month quit rates and
Figure 2 Scatterplot of incremental cost per QALY gained with 95% ellipse and willingness-to-pay (WTP) AU$20,000 per QALY gained.
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unstable. Further research on smoking-cessation quit rates
following genetic testing is needed to improve the validity
of the values used in our model and reduce the uncer-
tainty of our findings.
Our ICER of $34,687 per QALY gained would be
considered cost-effective in relation to accepted thresh-
olds for pharmacological health care treatments in
Australia [27]. However, given that we are not asses-
sing a pharmaceutical and that other ICERs of smoking
cessation options are among the lowest of all health
interventions, we used a $20,000 acceptable threshold
[5]. Several studies have shown better health outcomes
and cost-savings are possible for varenicline [26,28]
bupropion [28], and community pharmacy-led [29]
programs. In this context, it would seem that our
genetic testing strategy is a relatively poor investment.
However, with at least 30 published studies providing
evidence that a wide variety of smoking-cessation
interventions are cost effective, these findings may be
less favourable because most studies have overesti-
mated long-term effectiveness due to assumptions
made with smoking relapse rates or evaluation time
frames being too short [30]. In our study, the use of
improved epidemiological data on the risk of develop-
ing lung cancer separating risk estimates by gender,
time since quitting and heavy/light smoking patterns
[18] should provide more precise cost-effectiveness
estimates [31].
Traditionally, men are heavier smokers than women
and their relative risk of lung cancer is higher. This
explains the lower (more favourable) ICERs for men
b e c a u s et h e yh a v er e l a t i v e l yh i g h e rn u m b e r so fl i f e -
years to gain from stopping smoking [5,25]. However,
due to the large uncertainty in the model, differences
between men and women were tenuous. The benefits
of smoking-cessation can occur at any age of quitting
however, the risk of lung cancer among ex-smokers
versus non-smokers remains elevated even after more
than 40 years of cessation [9]. Our findings are in con-
trast to other studies where smoking-cessation among
younger cohorts has more favourable cost-effectiveness
than for older cohorts. Our opposite finding results
from the fact that a given percentage of people who
quit at 12 months are assumed to relapse each year,
meaning that some (younger) people will start smoking
again before the benefits of not smoking (avoided can-
cer) are realized. Additional research is need to iden-
tify whether relapse rates for younger smokers would
in fact remain low after receiving positive results from
a genetic test.
When our model was re-assessed for 30 year olds, the
long-term effects were severely eroded due to discount-
ing and relapse rates. Therefore, the overall effectiveness
was very small, inflating the cost-effectiveness ratio.
This finding would indicate that the genetic testing arm
is potentially suitable only in older (at least 50 year
olds), long-term smokers or that the NRT and counsel-
ling needs to be repeatedly offered in relapsed smokers
[30] and is not cost-effective as a one-off intervention.
Our choice of relapse rates is an important variable in
our model both in terms of the values used, which were
taken from a meta-analysis [15], and the 35 year model
duration. These have a combined effect of having a
cumulative lifetime relapse of 78% (subject to some
quitters dying before they are able to relapse), consider-
ably higher than studies using Markov models with life-
time relapse rates of 35% [4,25]. When the base case
relapse rates were halved and closer to those used pre-
viously, the cost-effectiveness ratios were substantially
lower; $18,623 (95%CI $5,897, $49,228).
While our model was responsive to an ageing cohort
and other time-dependent variables, some limitations
are apparent and a number of assumptions were neces-
sary. Data estimates are based on those available in pub-
lished randomized controlled trials and may not reflect
real-world practice (e.g., overestimated effects or com-
pliance from experimental trial data). It is acknowledged
that many individuals permanently cease smoking on
their own accord with no psychological or pharmacolo-
gical assistance. The present study examines the relative
effectiveness of a smoking cessation program compared
with a smoking cessation program given in conjunction
with a genetic test. Extensive sensitivity analyses
explored parameter uncertainty and aspects of the struc-
tural uncertainty (e.g., different cohort profiles). We
relied on a single, randomized clinical trial by McBride
et al. (2002) for a critical estimate, quit rate at
12-months following the genetic test [12]. This study
was US-based and involved a largely African-American
lower-socioeconomic cohort. Arguably, McBride et al.’s
sample of mostly lower-socioeconomic smokers may be
a difficult group to intervene in but likely to be relevant
and generalisable to other settings like Australia where a
higher proportion of disadvantaged people also smoke.
Potentially adverse consequences of genetic testing
include emotional distress, concerns about discrimina-
tion and implications for telling family members positive
results. These issues were omitted from our analysis.
Our results relate to QALYs gained from preventing
lung cancer onset and we did not incorporate improved
survival gains due to the potential avoidance of other
major diseases linked to smoking (e.g., heart disease,
COPD, diabetes). Again, the impact is that our effects
may be underestimated and overall ICERs conservative.
A further limitation of the study was the omission of
the potential implications of interactions between the
level of susceptibility, test properties and quit rates that
Gordon et al. Cost Effectiveness and Resource Allocation 2010, 8:18
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cing further uncertainty. Based on McBride’sf i n d i n g s ,
33% of the participants in the GT arm had a positive
genetic test for the missing gene GSTM1 for elevated
susceptibility to lung cancer. However, quit rates in
these participants were similar to those with negative
tests and therefore behavior change was not hindered
by the GT results. This finding is supported by our
own pilot work with further results on this issue
forthcoming.
Lung cancer is the leading cause of cancer death in
many developed countries and the prognosis is poor
with a 1-year survival of 34% and 5-year survival of 12%
[32]. Although the risk of lung cancer is small in indivi-
duals with ‘at risk’ genotypes, lung cancer is a common
cancer and therefore those with a genetic susceptibility
affects a high absolute number of smokers [8]. Further
research on genetic susceptibility and molecular epide-
miology in lung cancer alongside overall risk assess-
ments [7] remains important work before public health
approaches of screening, targeted smoking-cessation
programs or other preventive measures are adopted [8].
At the same time, commercial availability and consumer
interest in genetic testing is increasing and may create
added pressure for insurance companies or governments
to subsidize their costs [11]. To date, the evidence to
support effective smoking-cessation by informing indivi-
duals of their own genetic risk of lung cancer is promis-
ing but weak [10,12]. Genetic testing strategies rely on
successful doctor-patient communication and must be
ethical, results accurately conveyed and understood by
patients [11].
Conclusion
In certain circumstances, specifically, if a smoking-
cessation program delivering a genetic test, NRT and
counselling produced a 12-month quit rate of at least
12.4% then it would represent a potentially sound
health care investment for 50 year old heavy smokers.
Overall, our findings showed that a genetic test option
in addition to the use of NRT and counselling would
produce very similar costs and effects than NRT and
counselling alone. Further research on the quit rates at
12 months and beyond following a genetic testing
strategy is required to strengthen our findings.
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